Lidothol
Product Images NDC 83881-441

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lidothol (NDC 83881-441). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinic Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Box (83881 441 15)

LIDOTHOL Lidocaine 4% and Menthol 1% Patch packaging label by Clinic Pharma. The label shows the product name, active ingredients percentages, prescription only mark, quantity of 15 patches, and dimensions of each patch. The label includes dosage and administration instructions, list of inactive ingredients, a warning, barcode, and Clinic Pharma contact information.*

FDA Label Image

Fig1 (Fig1)

A pharmacokinetic curve showing plasma lidocaine concentration (ng/mL) over a 72-hour period. The graph features three distinct peaks indicating fluctuations in plasma levels at various hours, with concentrations ranging from 0 to approximately 120 ng/mL.*

FDA Label Image

Lidocaine (Lidocaine)

Chemical structure diagram of the active ingredient in LIDOTHOL, showing a substituted aromatic amide with diethyl amine and methyl groups attached to the benzene ring.*

FDA Label Image

Menthol (Menthol)

Chemical structure of Lidocaine as depicted on the image, showing a cyclohexane ring with hydroxyl and methyl groups attached.*

FDA Label Image

Mentholpath (Pathway)

A diagram illustrating the proposed metabolic pathway of menthol. It shows the chemical structure of menthol at the center with arrows indicating conversion to various metabolites including para-Menthane-3,7-diol, para-Menthane-3,9-diol, para-Menthane-3,8-diol, 3,8-Dihydro-para-Menthane-7-carboxylic acid, and Menthol-9-carboxylic acid. The diagram also notes the routes of excretion through urine and feces, and the presence of enterohepatic circulation.*

FDA Label Image

Table1 (Table1)

Table presents the absorption data of lidocaine from Lidocaine 5% Patch applied to the back of 15 normal volunteers over 12 hours. It includes application site area, dose absorbed, maximum plasma concentration (Cmax), and elimination half-life (Tmax).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.